What it sells
Immunotherapy for hard-to-treat solid tumours
Business model breakdown
Buyer: who owns the budget?
UnverifiedPharma partners and clinical/oncology stakeholders (licensing); patients are end beneficiaries.
Workflow: what inputs become what output?
Off-the-shelf tumor-cell banks stimulated to reveal cancer antigens, developed into in vivo immunotherapies for solid tumors (colorectal cancer focus).
Economics: what it saves and how it charges
Pre-commercial biotech funded by EUR 38M strategic funding; platform claims scalability and lower cost; no product revenue.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-07-22 | Series A extension | €11M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.